| Business Summary | | Biofield
Corp.
is
a
medical
technology
company
that
has
developed
a
system
for
detecting
breast
cancer
in
a
non-invasive
procedure.
The
Company's
technology
is
based
on
the
principle
that
epithelial
cancers,
such
as
cancer
of
the
breast,
ovaries,
skin,
prostate
and
colon,
are
characterized
by
small
changes
in
the
electrical
charge
of
the
affected
tissue.
Biofield's
breast
cancer
diagnostic
device,
the
Biofield
Diagnostic
System,
employs
single-use
sensors,
designed
by
the
Company,
and
a
measurement
device
to
detect
and
analyze
changes
associated
with
the
development
of
epithelial
cancers,
such
as
breast
cancer.
The
Biofield
Diagnostic
System
takes
multiple
readings
from
an
array
of
test
points
on
the
skin
surface
of
the
symptomatic
breast
and
asymptomatic
breast
to
measure
differentials
that
may
exist
between
test
points.
The
device
generally
is
intended
to
be
used
by
physicians
or
by
trained
medical
technicians
under
the
supervision
of
a
physician. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biofield
Corp.,
a
medical
technology
company,
has
developed
a
system
for
detecting
breast
cancer
through
the
skin
in
a
non-invasive
procedure.
Biofield's
system
employs
single-use
sensors
and
a
measurement
device
to
detect
and
analyze
changes
in
cellular
electrical
charge
distributions.
For
the
six
months
ended
6/01,
the
Company
reported
no
revenues.
Net
loss
rose
35%
to
$876
thousand.
Results
reflect
the
Company's
efforts
to
build
infrastructure
and
resume
its
operations. | More
from
Market Guide: Significant
Developments |
| | |
| Position | David Long, Jr., M.D., Ph.D., 70 | Chairman,
CEO | Anita Thibeault | Pres
and Acting VP of Regulatory/Clinical Affairs and Quality Assurance | John Stephens | Sr.
VP, COO, Treasurer | Nancy Bruyneel | VP,
Worldwide Sales and Marketing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|